<DOC>
	<DOCNO>NCT00749320</DOCNO>
	<brief_summary>The purpose study assess magnetic resonance imaging ( MRI ) tool track tumor growth renal cell carcinoma participant receive clinical treatment therapy sunitinib pazopanib . An MRI sophisticated type scan us powerful magnet make clear image focus detailed medical information participant abdomen pelvis . This image do study use ASL MRI technique allow u see blood flow change possibly may indicate tumor growth .</brief_summary>
	<brief_title>Arterial Spin Labeling Blood Flow MRI Evaluation Response Antiangiogenic Targeted Therapies Renal Cell Carcinoma ( RCC )</brief_title>
	<detailed_description>- MRI 's perform specific time point participant treatment renal cell carcinoma drug sunitinib pazopanib . These ASL MRI 's performed baseline , 2 week upon initiation therapy sunitinib/pazopanib , cycle 2 and/or cycle 4 therapy , end therapy . - The MRI test participant do Beth Israel Deaconess Medical Center .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>Patients diagnose metastatic renal cell carcinoma initiate sunitinib pazopanib Enrolled protocol 06105 , `` Collection specimens clinical data patient renal cell carcinoma treat targeted therapy , '' receive Pazopanib part routine clinical care . Found tumor 2.5cm great determine CT image Candidate lesion ASL MRI 2.5cm great . Order preference lesion location follow : abdominal lesion , bone lesion chest lesion Contraindication MRI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>MRI</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Pazopanib</keyword>
</DOC>